Logo

Genentech Reports Results of Polivy (polatuzumab vedotin-piiq) + R-CHP in P-III POLARIX Trial for the Treatment of Diffuse Large B-Cell Lymphoma

Share this
Genentech Reports Results of Polivy (polatuzumab vedotin-piiq) + R-CHP in P-III POLARIX Trial for the Treatment of Diffuse Large B-Cell Lymphoma

Genentech Reports Results of Polivy (polatuzumab vedotin-piiq) + R-CHP in P-III POLARIX Trial for the Treatment of Diffuse Large B-Cell Lymphoma

Shots:

  • The P-III POLARIX trial evaluates the efficacy- safety- and PK of Polivy + R-CHP vs R-CHOP in 879 patients in a ratio (1:1) with previously untreated DLBCL for 6 cycles- followed by Rituxan for 2cycles; or R-CHOP + Polivy PBO for 6 cycles- followed by 2 cycles of Rituxan. The trial is being conducted in collaboration with LYSA & LYSARC
  • The trial met its 1EPs that demonstrating the improvement in PFS. Additionally- the safety results were consistent with previous trials. The results will be submitted to health authorities globally
  • Polivy is currently used as an off-the-shelf- FD treatment option and approved in combination with bendamustine and Rituxan for R/R DLBCL in 60+ countries globally- including in the EU & US

| Ref: Businesswire | Image: Xconomy

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions